Добірка наукової літератури з теми "Anti-HER2 therapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Anti-HER2 therapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Anti-HER2 therapy"
Pospíšková, Markéta, and Milan Kohoutek. "Breast cancer a chronic disease? The Anti-HER2 therapy." Klinická farmakologie a farmacie 30, no. 4 (December 1, 2016): 28–30. http://dx.doi.org/10.36290/far.2016.032.
Повний текст джерелаNahleh, Zeina A., Elizabeth B. Elimimian, Leah C. Elson, Brian Hobbs, Wei Wei, and Cassann N. Blake. "Endocrine Therapy Plus Anti-HER2 Therapy as Adjuvant Systemic Therapy for Luminal HER2-Positive Breast Cancer: An Analysis of the National Cancer Database." Breast Cancer: Basic and Clinical Research 14 (January 2020): 117822342094569. http://dx.doi.org/10.1177/1178223420945694.
Повний текст джерелаBabar, Tania, Christopher Blomberg, Eileen Hoffner, and Xinhua Yan. "Anti-HER2 Cancer Therapy and Cardiotoxicity." Current Pharmaceutical Design 20, no. 30 (August 31, 2014): 4911–19. http://dx.doi.org/10.2174/1381612820666140604145037.
Повний текст джерелаLück, Hans-Joachim, Michael Untch, Christian Jackisch, Christoph Zielinski, and Rupert Bartsch. "Optimal Sequencing of Anti-HER2 Therapy." Breast Care 9, no. 2 (2014): 138. http://dx.doi.org/10.1159/000362300.
Повний текст джерелаMartínez-Jañez, Noelia, Ignacio Chacón, Ana de Juan, Luis Cruz-Merino, Sònia del Barco, Isaura Fernández, Paula García-Teijido, et al. "Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel." Breast Care 11, no. 2 (2016): 133–38. http://dx.doi.org/10.1159/000443601.
Повний текст джерелаCrespo, James, Hongxia Sun, Jimin Wu, Qingqing Ding, Guilin Tang, Melissa Robinson, Hui Chen, Aysegul A. Sahin, and Bora Lim. "HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14729-e14729. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14729.
Повний текст джерелаMehta, Sandhya, Jinlin Song, Melissa Pavilack, Jipan Xie, Xiaoyu Nie, Mohini Vembusubramanian, and Jackie Kwong. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, no. 29_suppl (October 10, 2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.
Повний текст джерелаKatayama, Ayaka, Islam M. Miligy, Sho Shiino, Michael S. Toss, Karim Eldib, Sasagu Kurozumi, Cecily M. Quinn, et al. "Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer." Modern Pathology 34, no. 7 (February 1, 2021): 1271–81. http://dx.doi.org/10.1038/s41379-021-00738-5.
Повний текст джерелаPetráková, Katarína. "Residual disease after neoadjuvant systemic anti-HER2 therapy: the KATHERINE trial." Onkologie 14, no. 2 (June 2, 2020): 93–95. http://dx.doi.org/10.36290/xon.2020.017.
Повний текст джерелаRaghav, Kanwal, Jonathan M. Loree, Jeffrey S. Morris, Michael J. Overman, Ruoxi Yu, Funda Meric-Bernstam, David Menter, et al. "Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer." JCO Precision Oncology, no. 3 (December 2019): 1–13. http://dx.doi.org/10.1200/po.18.00226.
Повний текст джерелаДисертації з теми "Anti-HER2 therapy"
VITALE, STEFANIA. "Role of endocrine therapy in combination with anti-HER2 therapy and CDK4/6 inhibitors in hormone receptor positive/HER2 positive breast cancer." Doctoral thesis, Università di Siena, 2019. http://hdl.handle.net/11365/1073185.
Повний текст джерелаHashimoto, Kenji. "Investigating a role of HER3 in anti-HER2 target therapy in breast cancer." Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:39025871-f32f-4e38-bd14-c13dbc9301f6.
Повний текст джерелаGuardia, Valenzuela Cristina 1990. "Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer." Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/668327.
Повний текст джерелаHER2-positive breast cancer (BC) is an aggressive subtype of this disease. The development of anti-HER2 targeted therapies, particularly the monoclonal antibody (Mab) trastuzumab, significantly improved its otherwise poor prognosis. More recently, another Mab called pertuzumab, has further improved the efficacy of trastuzumab, yet no all patients benefit from the combination of the two Mabs. A proportion of HER2-breast cancer patients will not benefit from anti-HER2 agents, and will ultimately die as a consequence of innate or acquired drug resistance mechanisms. Tumours consist not only of heterogeneous populations of cancer cells, but also of the tumour microenvironment (TME). In recent years, increasing evidence has shown that cancer-associated fibroblasts (CAFs; an abundant stromal cell population within the TME), directly support tumorigenesis and promote therapy resistance. However, at the beginning of this PhD study, there was little published work on the role of CAFs on anti-HER2 targeted therapy resistance. The work presented in this doctoral thesis supported a role of CAFs in tumour resistance to anti-HER2 targeted therapies in HER2+ breast cancer through paracrine secretion of soluble molecules that ultimately will promote breast cancer survival and therapy resistance.
Rieker, Marcel. "Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors." Phd thesis, Shaker Verlag GmbH, 2020. https://tuprints.ulb.tu-darmstadt.de/8615/7/2019-06-13_PhD_thesis_Rieker.pdf.
Повний текст джерелаOechsle, Crystal Mae. "The Use and Enhancement of Anti-Cancer Vaccine Therapy with Low-Toxicity Drugs for the Treatment of HER2 Positive Breast Cancer." Kent State University / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=kent1561121654968093.
Повний текст джерелаRieker, Marcel [Verfasser]. "Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors / Marcel Rieker." Düren : Shaker, 2019. http://d-nb.info/1198600004/34.
Повний текст джерелаRieker, Marcel [Verfasser], Harald [Akademischer Betreuer] Kolmar, and Felix [Akademischer Betreuer] Hausch. "Targeted Combination Therapy: Discovery and Evaluation of Synergistic Anticancer Effects of Anti-HER2-Duocarmycin Antibody-Drug Conjugates Combined with ATR Inhibitors / Marcel Rieker ; Harald Kolmar, Felix Hausch." Darmstadt : Universitäts- und Landesbibliothek Darmstadt, 2020. http://d-nb.info/1202922872/34.
Повний текст джерелаGuisier, Florian. "Contribution à l'identification de marqueurs de la réponse des carcinomes bronchiques non à petites cellules aux immunothérapies Anti-PD1 immunotherapy for NSCLC with actionable oncogenic driver mutations Janus or Hydra : the many faces of T helper cells in the human tumour microenvironment A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer Efficacy and safety of anti-PD-1 immunotherapy in pretreated NSCLC patients with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018." Thesis, Normandie, 2019. http://www.theses.fr/2019NORMR148.
Повний текст джерелаSince 2015, anti-PD1/PD-L1 immunotherapy has emerged as a standard of care for non-small cell lung cancer (NSCLC), demonstrating a higher rate of long-term control of stage IV disease. Nonetheless, most patients do not derive benefit from these drugs. Reliable biomarkers are needed to better select patients for immunotherapy. Studying a mouse model of NSCLC, we identified tumor volume as a predictive marker of response to anti-PD1 therapy. We confirmed this role in a cohort of 48 NSCLC patients treated with Nivolumab, in whom metabolic tumor volume was assessed on pretherapeutic PET-scan. Moreover, in our mouse model, debulking surgery enhanced the efficacy of anti-PD1 treatment. In a second study, we analysed the efficacy of anti-PD1/PD-L1 treatment in NSCLC patients with BRAF, MET or HER2 mutations or RET translocation. These subgroups of patients were overlooked in clinical trials and previous studies suggest they are not good candidates for immunotherapy. We collected data from 107 patients in 21 centers : -26 BRAF-V600, 18 BRAF-nonV600, 30 MET, 23 HER2, 9 RET. Response rates to anti-PD1/PD-L1 treatment were 26%, 33%, 27%, 38% and 38%, respectively. These are close to the ones observed in unselected NSCLC patients. Our results emphasize the need for more studies in these patients, since some of them derive durable benefit from anti-PD1/PD-L1 treatment
Частини книг з теми "Anti-HER2 therapy"
Barrios, Carlos, and Alessandra Morelle. "Anti-HER2 Adjuvant Therapy." In Breast Diseases, 497–508. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-13636-9_60.
Повний текст джерелаTower, Amelia, Ruta D. Rao, Kalliopi P. Siziopikou, Melody A. Cobleigh, and Thomas B. Julian. "Anti-HER2/neu Therapy in DCIS." In Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer, 99–108. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2035-8_10.
Повний текст джерелаTheile, Dirk, Gal Lenz, Jamil A. Momand, and Susan E. Kane. "Resistance to HER2-Targeted Therapy." In Resistance to Targeted Anti-Cancer Therapeutics, 35–88. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-70142-4_2.
Повний текст джерелаNahta, Rita. "Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer." In Resistance to Targeted Anti-Cancer Therapeutics, 191–221. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7_7.
Повний текст джерелаCrook, Tim, Su Li, and Peter Harper. "Medical management of breast cancer." In Oxford Textbook of Medicine, edited by Tim Eisen, 505–8. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0051.
Повний текст джерела"Molecularly-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER2-Targeted Therapy, mTOR Inhibitor and Antiangiogenic Therapy." In Frontiers in Anti-Cancer Drug Discovery, Volume 4, edited by Teruhiko Fujii, Keisuke Miwa, Tomoyuki Ushijima, Mototsugu Matsunaga, Masaru Fukahori, Kotaro Yuge, Uhi Toh, et al., 157–228. BENTHAM SCIENCE PUBLISHERS, 2014. http://dx.doi.org/10.2174/978160859225114040006.
Повний текст джерелаТези доповідей конференцій з теми "Anti-HER2 therapy"
Metzger-Filho, O., S. Mandrekar, S. Loibl, E. Ciruelos, L. Gianni, E. Lim, K. Miller, et al. "Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-ot3-05-07.
Повний текст джерелаArima, Yoshimi, Mari Hosonaga, and Hideyuki Saya. "Abstract 3331: CD24 promotes HER2 signaling pathways and CD24 inhibition sensitizes anti-HER2 therapy in breast cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-3331.
Повний текст джерелаLiu, Yunhua, Xiaoming He, Xiongbin Lu, and Xinna Zhang. "Abstract 3803: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-3803.
Повний текст джерелаLiu, Yunhua, Xiaoming He, Xiongbin Lu, and Xinna Zhang. "Abstract 3803: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-3803.
Повний текст джерелаQin, You, Hannah E. Dobson, Frank I. Comer, Alfred E. Chang, Max S. Wicha, and Qiao Li. "Abstract 514: Specific anti-HER2 host immunity conferred by HER2-targeted antibody drug conjugate therapy and checkpoint blockade." In Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-514.
Повний текст джерелаBorrero-García, Luis Daniel, Brian Vidal, and Suranganie Dharmawardhane. "Abstract 1824: Mechanisms of resistance to anti-EGFR/HER2 therapy in breast cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1824.
Повний текст джерелаIm, S.-A., Y.-J. Bang, D.-Y. Oh, G. Giaccone, T. Bauer, J. Nordstrom, H. Li, et al. "Abstract P6-18-11: Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+ breast cancer patients with prior anti-HER2 therapy." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-18-11.
Повний текст джерелаSethunath, Vidyalakshmi, Huizhong Hu, Carmine DeAngelis, Jamunarani Veeraraghavan, Lanfang Qin, Martin Shea, Tamika Mitchell, et al. "Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4757.
Повний текст джерелаSethunath, Vidyalakshmi, Huizhong Hu, Carmine DeAngelis, Jamunarani Veeraraghavan, Lanfang Qin, Martin Shea, Tamika Mitchell, et al. "Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4757.
Повний текст джерелаJiang, Z., L. Li, Y. Liu, T. Wang, S. Zhang, Y. Yuan, L. Bian, Q. Liu, and F. Qi. "Abstract OT1-1-04: HER2 status of circulating tumor cells in HER2-positive metastatic breast cancer patients: A valuable biomarker in anti-HER2 therapy." In Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-ot1-1-04.
Повний текст джерелаЗвіти організацій з теми "Anti-HER2 therapy"
Strube, Randall. Anti-HER2/Toxin Expressing Lymphocytes for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, May 2001. http://dx.doi.org/10.21236/ada395157.
Повний текст джерелаStrobe, Randall. Anti-HER2/Toxin Expressing Lymphocytes for Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, May 2000. http://dx.doi.org/10.21236/ada393070.
Повний текст джерелаGuo, Kevin, Rebecca Hawkins, and Bonnie Wu. Engineering a Cell-Penetrating Anti-HER2 Monoclonal Antibody for Efficient Delivery of Gold Nanoparticles into Cancer Cells To Enhance X-Ray Cancer Radiation Therapy. Journal of Young Investigators, February 2020. http://dx.doi.org/10.22186/jyi.38.2.13-22.
Повний текст джерела